MiMedx to Present at Jefferies 2017 London Healthcare Conference

Wednesday, November 8, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative

and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at Jefferies 2017 London Healthcare Conference in London,
UK
. Parker H. "Pete" Petit, Chairman & CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP & Chief Commercialization Officer and I. Mark Landy, SVP Strategic Initiatives, are scheduled to present on Thursday, November 16, 2017 at 9:00 a.m. eastern time, (2:00 p.m. London time) at the Waldorf Hilton in London, UK.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.

About MiMedxMiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.   MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

View original content:http://www.prnewswire.com/news-releases/mimedx-to-present-at-jefferies-2017-london-healthcare-conference-300551854.html

SOURCE MiMedx Group, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store